Background: Older adults are at an increased risk of delirium because of age, polypharmacy, multiple comorbidities, frailty, and acute illness. Although medication-induced delirium in older adults is well understood, limited population-level evidence is available, particularly on combinations of medications associated with delirium in older adults.
Objectives: We aimed to apply association rule analysis to identify drug combinations contributing to delirium risk in adults aged 65 and older using a case-time-control design.
Method: We sourced a nationwide representative sample of New Zealander's aged ≥65 years from the pharmaceutical collections and hospital discharge information. Prescription records (2005-2015) were obtained from New Zealand pharmaceutical collections (Pharms). Medication exposures were coded as binary variables (exposed vs. not exposed) at the individual drug level. All medications, including antimicrobials, antihistamines, diuretics, opioids, and nonsteroidal anti-inflammatory medications, were considered drugs of interest. The first-time coded diagnosis of delirium was extracted from the National Minimal Dataset (NMDS). A unique patient identifier linked the prescription dataset to the event dataset to set up a case-time-control cohort, indexed at the first delirium event. Association rules were then applied to identify frequent drug combinations in the case and the control periods (l-day with a 35-day washout period) that are statistically associated with delirium, and the association was tested by computing a time-trend adjusted matched odds-ratio (MOR) and its 95% confidence interval (CI).
Results: We identified 28 503 individuals (mean age 84.1 years) from 2005 to 2015 with delirium. Our combined association rule and case-time-control analysis identified several drug classes, including antipsychotics, benzodiazepines, opioids, and diuretics associated with delirium. Our analysis also identified frequently used drug combinations that are associated with delirium. Examples include combined exposures to quetiapine and furosemide (MOR = 6.17; 95%CI = [2.05-18.54]), haloperidol (MOR = 4.81; 95%CI = [3.16-6.69]), combined exposures to furosemide, omeprazole, and lorazepam (MOR = 3.94; 95%CI = [3.03-5.10]), and fentanyl exposure (MOR = 3.46; 95%CI [2.05-9.21]).
Conclusion: The association rule method applied to a case-time-control design is a novel approach to identifying drug combinations contributing to delirium with adjustment for any temporal trends in exposures. The study provides new insight into the combination of medicines linked to delirium.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pds.5292 | DOI Listing |
Background: Ceftazidime-avibactam and colistin are antibiotics of new and regaining importance used for the treatment of infections caused by multidrug-resistant organisms. The broth microdilution (BMD) test recommended for detecting colistin sensitivity is labor-intensive and difficult to perform under routine conditions. There is a need for alternative methods that produce fast and reliable results in routine laboratory studies.
View Article and Find Full Text PDFParasit Vectors
March 2025
Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Background: While generally harmless to dogs, the cestode species Echinococcus granulosus and Echinococcus multilocularis have significant zoonotic importance, causing cystic echinococcosis and alveolar echinococcosis in humans, respectively. Regular deworming is essential to treat intestinal cestode infections in dogs and to reduce environmental egg contamination and thus the subsequent zoonotic risk of infection to intermediate hosts and humans. The studies described here evaluated the efficacy of a new novel chewable tablet combination containing lotilaner, moxidectin, praziquantel and pyrantel (Credelio Quattro, Elanco Animal Health) against E.
View Article and Find Full Text PDFCurr Allergy Asthma Rep
March 2025
Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Crete, Greece.
Clin Lung Cancer
February 2025
The Helmsley Cancer Center, The Hebrew University of Jerusalem Shaare Zedek Medical Center Shmuel Beit 12, Jerusalem, Israel. Electronic address:
Introduction: Despite recent advances in immunotherapy combinations for extensive-stage small cell lung cancer (ES-SCLC), rapid disease progression following chemotherapy discontinuation remains a significant challenge. While the addition of pembrolizumab to platinum-etoposide has demonstrated a modest improvement in progression-free survival (PFS), there is an urgent need for more effective maintenance strategies. Sacituzumab govitecan (SG), an antibody-drug conjugate targeting Trop-2, has shown promising activity in pretreated ES-SCLC.
View Article and Find Full Text PDFInt J Pharm
March 2025
University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address:
The subcutaneous administration of biopharmaceuticals is advantageous over intravenous administration, particularly with regard to improved patient compliance. However, in highly concentrated protein formulations lower viscosity of the formulation and stability of the protein is difficult to achieve. One approach involves using the viscosity-reducing excipients to diminish the interactions between protein molecules.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!